Biosimilars in inflammatory bowel disease

被引：2
|
作者：
Moore, Gregory T. [1 ,2 ]
机构：
[1] Monash Hlth, Clayton, Vic, Australia
[2] Monash Univ, Clayton, Vic, Australia
来源：
MEDICAL JOURNAL OF AUSTRALIA | 2016年 / 205卷 / 07期
关键词：
D O I：
10.5694/mja16.00775
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：294 / 295
页数：2
相关论文
共 50 条
  • [31] Adalimumab originator and biosimilars in global inflammatory bowel disease treatment
    Yiu, Tsz Hong
    Nakase, Hiroshi
    Leung, Wai Keung
    Lin, Huiyu
    Banerjee, Rupa
    Anderson, Emilia
    Leong, Rupert
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 173 - 174
  • [32] BIOSIMILARS SLOW TO GAIN TRACTION FOR INFLAMMATORY BOWEL DISEASE IN THE US
    Zweig, Steven J.
    BIOTECHNOLOGY LAW REPORT, 2020, 39 (03) : 163 - 163
  • [33] Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017
    Frank I. Scott
    Gary R. Lichtenstein
    Current Treatment Options in Gastroenterology, 2018, 16 (1) : 147 - 164
  • [34] Patient Perceptions Regarding the Use of Biosimilars in Inflammatory Bowel Disease
    Pineles, David
    Arsuaga, Amy
    Malter, Lisa B.
    Bosworth, Brian P.
    Hudesman, David P.
    Chang, Shannon
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S418 - S419
  • [35] Overview of Biosimilars in Inflammatory Bowel Diseases
    Feagins, Linda A.
    Gold, Stephanie
    Steinlauf, Adam F.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (02) : 229 - 232
  • [36] Biosimilars in the therapy of inflammatory bowel diseases
    Hlavaty, Tibor
    Letkovsky, Juraj
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 26 (06) : 581 - 587
  • [37] Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease
    Argueelles-Arias, Federico
    Hinojosa-del-Val, Joaquin
    Vera-Mendoza, Isabel
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2018, 110 (06) : 407 - 407
  • [38] Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
    Zeng, Zhen
    Lin, Hao
    Jiang, Mingshan
    Yuan, Jing
    Li, Xi
    Jia, Yongbin
    Yang, Li
    Zhang, Hu
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [39] Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia
    Anderson, Emilia
    Waller, Karen
    Tamilarasan, Aravind Gokul
    Lin, Huiyu
    Paramsothy, Sudarshan
    Leong, Rupert W.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (08) : 819 - 825
  • [40] Biosimilars in inflammatory bowel disease: A review of post-marketing experience
    Simona Deiana
    Tommaso Gabbani
    Vito Annese
    World Journal of Gastroenterology, 2017, (02) : 197 - 203
12345